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AbsTrACT
Aim To assess the impact of deprivation on diabetic 
retinopathy presentation and related treatment 
interventions, as observed within the UK hospital eye 
service.
Methods This is a multicentre, national diabetic 
retinopathy database study with anonymised data 
extraction across 22 centres from an electronic medical 
record system. The following were the inclusion 
criteria: all patients with diabetes and a recorded, 
structured diabetic retinopathy grade. The minimum 
data set included, for baseline, age and Index of 
Multiple Deprivation, based on residential postcode; 
and for all time points, visual acuity, ETDRS grading 
of retinopathy and maculopathy, and interventions 
(laser, intravitreal therapies and surgery). The main  
outcome measures were (1) visual acuity and binocular 
visual state, and (2) presence of sight-threatening 
complications and need for early treatment.
results 79 775 patients met the inclusion criteria. 
Deprivation was associated with later presentation in 
patients with diabetic eye disease: the OR of being sight-
impaired at entry into the hospital eye service (defined 
as 6/18 to better than 3/60 in the better seeing eye) 
was 1.29 (95% CI 1.20 to 1.39) for the most deprived 
decile vs 0.77 (95% CI 0.70 to 0.86) for the least 
deprived decile; the OR for being severely sight-impaired 
(3/60 or worse in the better seeing eye) was 1.17 (95% 
CI 0.90 to 1.55) for the most deprived decile vs 0.88 
(95% CI 0.61 to 1.27) for the least deprived decile 
(reference=fifth decile in all cases). There is also variation 
in sight-threatening complications at presentation and 
treatment undertaken: the least deprived deciles had 
lower chance of having a tractional retinal detachment 
(OR=0.48 and 0.58 for deciles 9 and 10, 95% CI 0.24 
to 0.90 and 0.29 to 1.09, respectively); in terms of 
accessing treatment, the rate of having a vitrectomy was 
lowest in the most deprived cohort (OR=0.34, 95% CI 
0.19 to 0.58).
Conclusions This large real-world study suggests that 
first presentation at a hospital eye clinic with visual loss 
or sight-threatening diabetic eye disease is associated 
with deprivation. These initial hospital visits represent the 
first opportunities to receive treatment and to formally 
engage with support services. Such patients are more 
likely to be sight-impaired or severely sight-impaired 
at presentation, and may need additional resources 
to engage with the hospital eye services over complex 
treatment schedules.
InTroduCTIon
Unequal distribution of wealth and other resources 
occurs in almost all societies.1 2 The WHO have 
outlined how health inequality may arise from 
differences in socioeconomic position.3 It is 
recognised that this inequality leads to ‘depriva-
tion’ in a proportion of society, and that this is not 
solely economic, but may include limited access to 
resources for cultural, social, knowledge or polit-
ical reasons.2 4 In the UK, the report Fair society, 
healthy lives (also known as ‘the Marmot review’ 
after its author) highlighted the extent to which 
health inequalities exist in the UK, and the profound 
impact of income deprivation on life expectancy 
and disability-free life expectancy. Although the 
influence of deprivation on health was already 
widely accepted, the Marmot review brought this 
issue firmly to the modern political consciousness 
of the UK.5 6
Quantifying this effect allows agencies to 
measure the greatest areas of unmet need, and 
to target resources to deal with specific depriva-
tion-related barriers to healthcare. Since 2000, the 
UK government has been measuring deprivation in 
England using the Index of Multiple Deprivation 
(IMD). The IMD splits deprivation into discrete, 
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quantifiable domains, including income, employment, health 
and disability, education, crime, barriers to housing, services, 
and living environment. These are collated at the level of small 
geographical areas known as lower layer super output areas 
(LSOAs), enabling deprivation to be estimated for an individual 
according to their residential area. IMD data have successfully 
been used to highlight social deprivation as an independent risk 
factor for many systemic diseases.5 In terms of eye disease, the 
IMD has been used to evaluate the impact of deprivation on 
low vision7 and a significant factor in the prevalence or presen-
tation of a number of specific eye conditions, including severe 
neovascular age-related macular degeneration,8 glaucoma9 10 
and cataract.11
In the global setting a number of studies have explored the 
potential influence of deprivation on the prevalence of diabetes, 
access to assessment and treatment, quality of glycaemic control, 
and diabetic complications; this has been evaluated in systematic 
reviews by Lindner et al for type 1 diabetes (2018) and Grintsova 
et al for type 2 diabetes (2014).12 13 In terms of diabetic eye 
disease most of the attention has focused on diabetic screening, 
particularly with regard to uptake, with studies showing the 
impact of deprivation across the world, including the USA,14–16 
Canada,17 UK,18–21 Korea,22 India23 and Tanzania.24 In addition 
to a lower uptake of screening in the more deprived groups, 
a number of studies have shown that there are higher rates of 
sight-threatening diabetic retinopathy (DR) in the most deprived 
groups.18 25 It should be noted that most published data are from 
screening programmes18 or population-based cohort studies,25 
and there are little data on whether the adverse impact of 
social deprivation is primarily around screening and access to 
secondary care, or whether it continues to have an impact once 
the patient is referred to the hospital eye service.26 27 In a small 
retrospective study from the UK, Lane et al26 found that social 
deprivation (as measured by the IMD score) was a risk factor for 
the late presentation of patients with proliferative diabetic reti-
nopathy (PDR) requiring urgent laser therapy, but that care (as 
measured by time to laser) was not significantly different after 
entry into the hospital eye service. In a prospective study from 
the USA, Roy et al did not find deprivation to be associated with 
progression to PDR, although it was associated with incidence of 
maculopathy.26 27 Both studies were relatively small in scale (508 
patients or less) and provide little information on progression 
within secondary care.
The use of electronic medical record (EMR) systems, which 
routinely gather clinically relevant data, provides the oppor-
tunity to analyse larger study cohorts than would be practical 
within a clinical trial. In the UK, the most widely used ophthalmic 
EMR has implemented a nationally defined minimum data set 
for DR that mandates recording of visual acuity status, and the 
minimum clinical signs necessary to allow automated grading 
of retinopathy and maculopathy grade after each consultation 
(as described in the UK DR EMR Reports 1–3).28–30 These data 
therefore enable a large-scale view of the severity of diabetic eye 
disease at presentation and its rate of progression over time. All 
interventions including laser procedures, intravitreal injections 
and ophthalmic operations are recorded, providing the oppor-
tunity to analyse access and delivery of treatment. The inclusion 
of IMD score as part of the core data set now enables us to test 
in a large ‘real-world’ cohort whether patients with higher levels 
of deprivation may present later to the hospital eye service in 
terms of their visual status and their development of sight-threat-
ening complications, and to assess variations in the treatment 
they receive.
MeThods
data collection
Anonymised data were remotely extracted from 22 centres 
using the same EMR system (Medisoft Ophthalmology, Medi-
soft, Leeds, UK). Each site is the only National Health Service 
(NHS) provider of DR care to their local population, and very 
few patients switch between providers or access care privately. 
Data were extracted through the EMR compulsory DR struc-
tured assessment module. The minimum data set included age, 
visual acuity at baseline and at all subsequent visits, episodes of 
intervention (laser, intravitreal therapy, surgical procedure and 
proxy-ETDRS for retinopathy/International Clinical Grading 
system grading of maculopathy at baseline and all subsequent 
visits), and IMD score at baseline.
Index of Multiple deprivation
The EMR system includes data on residential address as stan-
dard. The LSOA for each postcode was identified and allocated 
to the IMD score for that area based on the English Indices of 
Deprivation 2015 (https://www. gov. uk/ government/ statistics/ 
english- indices- of- deprivation- 2015). The LSOA conversion was 
undertaken at source to avoid transfer of patient-identifiable 
data. The English Indices of Deprivation 2015 uses the LSOAs 
defined in the 2011 census, with evaluation of deprivation being 
primarily based on data taken from 2012 to 2013.
Inclusion criteria
The study includes eyes from patients with diabetes in whom 
a structured DR grade(s) and accompanying minimum data set 
had been recorded in the EMR.
Analysis
Three cohorts were considered. The ‘all diabetic cohort’ 
includes all patients who were recorded as diabetic and who 
had been given a DR grade. It was acknowledged, however, that 
this would include many ‘low risk’ patients who were referred 
for reasons other than their diabetic eye disease, for example, 
cataracts. Since the focus of this study was patients requiring 
secondary-level care for their diabetic eye disease, we identi-
fied two ‘high risk’ cohorts of interest: (1) the ‘early findings 
cohort’ and (2) the ‘early treatment cohort’. The ‘early findings 
cohort’ was defined as those patients who were noted to have 
sight-threatening complications within 2 months of their first 
visit (comprising treatment-requiring maculopathy, vitreous 
haemorrhage or tractional retinal detachment). The ‘early treat-
ment cohort’ was defined as those patients who required treat-
ment related to their diabetic eye disease within 2 months of 
entry into the hospital eye service.
Cohorts were stratified into their IMD deciles (1–10) according 
to their LSOA as described on https://www. gov. uk/ government/ 
statistics/ english- indices- of- deprivation- 2015. Decile 1 corre-
sponds to the most deprived group. Unless otherwise specified, 
the eye with worse presenting retinopathy level was chosen 
for analyses. If both eyes had the same retinopathy level, then 
one eye was chosen randomly. To provide an internal control 
and to deal with potential under-reporting from centres which 
might not use the EMR system beyond basic grading, analysis of 
sight-threatening complications of diabetic eye disease (diabetic 
macular oedema, vitreous haemorrhage and tractional retinal 
detachment) and of treatments was based on the subsets of 
patients who attended at centres where all relevant conditions 
and treatments had been recorded.
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Table 1 Cohort characteristics
early findings 
cohort
early treatment 
cohort
All patients with 
diabetes
n 15 169 6581 79 775
Mean age (SD) (years) 60.60 (13.80) 61.58 (16.64) 63.79 (15.18)
Gender
Male 9044 3705 44 646
Female 6125 2876 35 127
Unspecified 0 0 2
Mean visual acuity (SD) 
in the worse seeing eye 
(number of letters) 67.24 (23.63) 60.47 (28.66) 71.24 (23.04)
Diabetic retinopathy 
(% eyes)
No/mild diabetic 
retinopathy 38.8 36.1 64.6
Moderate NPDR 22.0 5.9 16.0
Severe NPDR 7.8 3.4 4.0
PDR 31.1 54.6 15.4
IMD decile (%)
1 14.0 18.6 15.9
2 16.3 15.6 15.4
3 13.7 12.9 12.9
4 12.4 10.4 11.2
5 9.1 8.2 8.7
6 8.3 8.4 8.6
7 7.4 7.4 7.7
8 6.8 6.2 6.6
9 7.0 6.8 7.0
10 5.0 5.6 5.8
IMD, Index of Multiple Deprivation; NPDR, non-proliferative diabetic retinopathy; 
PDR, proliferative diabetic retinopathy.
The primary outcome measure was best corrected visual status 
(by patient) at entry into the hospital eye service. Visual status 
was considered in three real-world categories: (1) retained ‘good 
vision’ in both eyes (better than 6/12 in the worse seeing eye); 
(2) sight-impaired (visual acuity=6/18 to better than 3/60 in the 
better seeing eye); and (3) severe sight impairment (3/60 or worse 
in the better seeing eye). It should be noted that these are not 
directly equivalent to ‘registration’ grades of sight impairment 
(previously described as ‘partially sighted’ and ‘blind’) for which 
qualification may be based on visual acuity alone or a combi-
nation of visual acuity and visual field impairment, and which 
therefore have a degree of subjectivity. Analysis was performed 
in ETDRS letter notation, using conversions as described for the 
1 m LogMAR (logarithm of the minimum angle of resolution) 
chart as per our previous studies.28 31 32
Statistical analysis was done using Ruby (www. ruby- lang. 
org) and R (www. r- project. org). For each outcome of interest, a 
logistic regression model was created with the fifth IMD decile 
set as the reference group.
Patient and public involvement
This multicentre study evaluating the interaction of depriva-
tion with DR across a broad section of England was directly 
informed by priorities identified during a James Lind Alliance 
priority setting partnership.33 Priorities identified by this multis-
takeholder process (including patients and carers) included the 
need to identify barriers to access in diabetic eye disease and 
to explore the non-medical factors that lead to differences in 
outcome. No patients or public were involved in the design of 
the study or in the numerical analysis. Two patient partners (who 
wish to remain anonymous) have provided patient commentary 
of the study, and will be involved in the dissemination of this 
work through providing patient commentaries to patient soci-
eties in both the eyes and vision sector and the diabetes sector for 
dissemination through written and electronic means.
resulTs
baseline characteristics
Data were extracted on 79 775 patients (one eye chosen per 
patient) with DR grades (including a grade of no DR) in the EMR 
who met the inclusion criteria (patients with diabetes in whom 
a structured DR grade and minimum data set were recorded). 
There were 44 646 male patients, 35 127 female patients and 
2 cases of unrecorded gender (table 1). At baseline, the study 
group comprised 8513 eyes with no apparent DR, 43 016 with 
mild non-proliferativediabetic retinopathy (NPDR), 12 757 
with moderate NPDR, 3221 with severe NPDR and 12 268 with 
PDR. At baseline, 12 581 eyes had maculopathy (any severity).
In the ‘early findings cohort’, there were 15 169 patients who 
met the inclusion criteria (9044 male patients, 6125 female 
patients and 0 case of unrecorded gender). In the ‘early treat-
ment cohort, there were 6581 patients who met the inclusion 
criteria (3705 male patients, 2876 female patients and 0 case of 
unrecorded gender).
Visual acuity and visual status at presentation
Visual acuity at presentation to the hospital eye service was 
inversely associated with the level of deprivation (figure 1). The 
mean visual acuity (SD) in the worse seeing eye for the whole 
diabetic cohort of 79 775 patients was 71.2 (23.0) letters, 
approximately equivalent to a Snellen score of 6/12-6/11.31
Visual status was considered in three real-world categories: (1) 
retained ‘good vision’ in both eyes (better than 6/12 in the worse 
seeing eye); (2) sight-impaired (visual acuity=6/18 to better than 
3/60 in the better seeing eye); and (3) severe sight impairment 
(3/60 or worse in the better seeing eye). The OR of having ‘good 
vision’ was 0.84 (95% CI 0.80 to 0.89) for the most deprived 
decile vs 1.21 (95% CI 1.12 to 1.30) for the least deprived 
decile. The OR of being ‘sight impaired’ was 1.29 (95% CI 1.20 
to 1.39) for the most deprived decile vs 0.77 (95% CI 0.70 to 
0.86) for the least deprived decile; the OR for being ‘severely 
sight impaired’ (3/60 or worse in the better seeing eye) was 1.17 
(95% CI 0.90 to 1.55) for the most deprived decile vs 0.88 (95% 
CI 0.61 to 1.27) for the least deprived decile (reference=fifth 
decile in all cases).
Presence of sight-threatening complications at presentation
The ‘early findings cohort’ of 15 169 patients had mean (SD) 
visual acuities of 67.2 (23.6) ETDRS letters at entry to the 
hospital service, equivalent to a Snellen score of 6/12-6/15. 
Nearly 40% of patients in this group had either severe NPDR 
or PDR. The relationship between deprivation and sight-threat-
ening complications of maculopathy, vitreous haemorrhage and 
tractional retinal detachment is shown in figure 2.
Maculopathy showed little variation across the IMD deciles, 
although there was a small but statistically significant reduction 
in maculopathy in both the most deprived (IMD1) and the least 
deprived (IMD10) deciles (OR=0.83 (95% CI 0.76 to 0.89 for 
IMD1); OR=0.85 (95% CI 0.77 to 0.94 for IMD10)). The pres-
ence of vitreous haemorrhage was not associated with depriva-
tion level. Tractional retinal detachment was least likely in the 
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Figure 1 The association of deprivation with worse visual acuity at point of entry into the hospital eye service for patients with diabetic eye disease. 
Deprivation is plotted per Index of Multiple Deprivation (IMD) decile with the most deprived being decile 1 and the least deprived being decile 10. OR 
is calculated for each decile in relation to decile 5. The chances of having preserved ‘good vision’ are negatively associated with worse deprivation, 
whereas the chances of being ‘sight-impaired’ or ‘severely sight-impaired’ are positively associated (see text for definitions). *P<0.05, **p<0.01, 
***p<0.001.
Figure 2 Deprivation and sight-threatening complications of diabetic eye disease. Deprivation is plotted per the Index of Multiple Deprivation (IMD) 
decile with the most deprived being decile 1 and the least deprived being decile 10. OR is calculated for each decile in relation to decile 5. *P<0.05, 
**p<0.01.
deciles with the least deprivation (OR for IMD decile 9, 0.48 
(95% CI 0.24 to 0.90); OR for IMD decile 10, 0.58 (95% CI 
0.29 to 1.09)).
requirement for early treatment for sight-threatening 
complications
The ‘early treatment cohort’ of 6581 patients had a mean (SD) 
visual acuity of 61.6 (16.6) ETDRS letters at entry to the hospital 
service, equivalent to a Snellen score of 6/15-6/19. Nearly 60% 
of patients in this group had either severe NPDR or PDR. The 
relationship between deprivation and treatment for sight-threat-
ening complications is shown in figure 3.
The strongest association noted was for vitrectomy, which was 
significantly less likely in the most deprived decile with an OR of 
0.34 (95% CI 0.19 to 0.58). Some variation was also noted for 
both injections for DMO, which was significantly more likely in 
the least deprived decile (OR=1.3 (95% CI 1.09 to 1.56)), and 
pan-retinal photocoagulation, which was significantly less likely 
(OR=0.75 (95% CI 0.59 to 0.94)).
dIsCussIon
Deprivation is a major determinant of health, being shown to 
be associated with late disease presentation and worse outcomes 
across a range of health problems. This analysis of over 75 
000 patients with diabetes taken from across 22 centres across 
England shows that the impact of deprivation extends to late 
presentation of diabetic eye disease. At the time of presenta-
tion to the hospital eye service, the likelihood of a patient with 
diabetes having lost significant vision (‘sight impaired’) is much 
higher in the most deprived decile (OR 1.29) than the least 
deprived decile (OR 0.77; both vs the fifth decile as a reference). 
There also appears to be an interaction with the patterns of 
sight-threatening complications seen (such as tractional retinal 
detachment) and the treatment that these patients receive.
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Figure 3 Deprivation and early treatment in diabetic eye disease. Deprivation is plotted per Index of Multiple Deprivation (IMD) decile with 
the most deprived being decile 1 and the least deprived being decile 10. OR is calculated for each decile in relation to decile 5. Patients in the 
most deprived decile have a significantly lower chance of having a vitrectomy despite similar rates of vitreous haemorrhage and tractional retinal 
detachment (compared with the reference). *p<0.05, **p<0.01, ***p<0.001.
Most larger scale studies of the effect of deprivation on 
diabetic eye disease do suggest an association, although it should 
be noted that there are important differences in the design and 
setting. First most are based on community screening data and 
not conducted within the hospital eye service. In the UK, Scanlon 
et al18 used IMD data to analyse the effect of deprivation on over 
13 000 patients seen as part of a national diabetes retinopathy 
screening programme. They did not find higher levels of depri-
vation to be associated with a higher prevalence of retinopathy 
per se but found that deprivation was associated with higher 
levels of sight-threatening retinopathy, which increased from 
11.9% in quintile 1 (least deprived) to 14.2% in quintile 5 (most 
deprived). In the USA, Westet al25 reported on 4774 Hispanics 
aged 40 years and over, compiled as part of the Proyecto VER 
Study. In this high-risk group the presence of diabetes was asso-
ciated with deprivation as measured by lower income and lower 
educational attainment, and the presence of PDR was associated 
with low income (OR=3.6, for developing PDR if income <$20 
000) after controlling for other factors.25
A second important difference in our analysis presented here 
is that our primary outcome is an outcome that is meaningful 
to patients—visual acuity or binocular visual status—rather 
than retinopathy grade per se. Visual status at the time of entry 
into the hospital eye service was considered in three real-world 
categories: ‘good vision’ in both eyes (sufficient for reading or 
driving), ‘sight impaired’ and ‘severely sight-impaired’. This is 
not to underestimate the importance of retinopathy grade, but 
to acknowledge that the importance of retinopathy is related to 
its functional impact on the patient (ie, loss of vision). The rela-
tionship of retinopathy to functional outcome is complex, but 
we are continuing to explore this in this cohort, using both the 
cross-sectional and longitudinal data available.
It is notable that a number of smaller studies have failed to 
detect an effect between deprivation and diabetic eye disease, 
but report a non-significant trend. We therefore contend that 
the failure to detect an effect of deprivation likely arose due to a 
lack of statistical power. For example, the study by Lim et al34 of 
1073 patients from the San Francisco mobile eye service noted 
that the level of severe retinopathy was more than twofold higher 
in the lowest income group, but this did not reach statistical 
significance. Some variation between the findings of studies may 
also be attributable to how deprivation has been assessed, with a 
number of studies assessing deprivation on only educational or 
financial criteria.35
The major strengths of our study include its scale, the use of 
a comprehensive deprivation assessment tool and its longitu-
dinal data. The scale of our study, which includes 79.775 eyes, is 
made possible by its ‘real world’ nature arising from the use of a 
standardised assessment framework within the most widely used 
ophthalmic EMR system in the UK. Our study includes data 
from 22 different centres from across the UK, which include 
urban and rural settings, with a wide range of ethnic and demo-
graphic profiles, providing a broader analysis of the situation in 
the UK than was possible in the single-area study by Scanlon et 
al.18 One of the great strengths of both the Scanlon study and 
ours is the use of the IMD tool to measure deprivation. The 
multiple components of the IMD tool provide a more complete 
assessment of deprivation than a simple assessment of income or 
level of educational attainment. The IMD tool includes assess-
ments of income, employment, health and disability, education, 
crime, barriers to housing, services and living environment.
In contrast to most studies in this area which are cross-sec-
tional in design, our study provides in-hospital data to evaluate 
treatment decisions. This has highlighted that in those patients 
who required treatment for sight-threatening complications of 
diabetes within 2 months of first hospital visit (the ‘early treat-
ment group’), there appears to be some variation in practice at 
the extreme ends of the deprivation spectrum. It is interesting 
to note that pars plana vitrectomy is significantly less common 
in the most deprived decile, despite having similar rates of both 
vitreous haemorrhage and tractional retinal detachment as most 
other deciles; indeed it is the least deprived deciles that appear 
to be relatively protected from presenting with tractional retinal 
detachment in the electronic record. Injection treatment for 
diabetic maculopathy was significantly more common in the 
least deprived decile, even though diabetic maculopathy was 
recorded significantly less commonly in this decile.
Although these differences in treatment pattern could reflect 
an underlying degree of inequity between groups of patients, the 
association is likely to be complex. The low rates of vitrectomy 
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in the most deprived cohorts could represent one or more of the 
disease factors—more advanced disease at presentation which is 
deemed to be beyond surgical repair; concomitant medical factors 
(eg, diabetes control, renal failure, uncontrolled hypertension) or 
social factors (employment, childcare responsibilities) that may 
have delayed treatment delivery beyond the 8-week limit used in 
this analysis; surgeon choice including justifiable understanding 
of risk and unjustified biases; and patient choice including vari-
ations in understanding risk, medical jargon. It is also possible 
that there is some effect from the less deprived deciles receiving 
part of their care in the private sector, although we believe that 
this is likely to be relatively minor given the distribution of NHS 
versus private care in the UK.36 These are important questions 
which would require more indepth qualitative work. Our study 
can however highlight these issues as being worthy of further 
investigation.
In the future, longitudinal data from our study will also enable 
us to evaluate whether the effect of deprivation continues after 
entry into the hospital eye service. We are now exploring the 
relationship between IMD score and progression of retinopathy 
to provide an estimate of rates of progression and decline in 
visual acuity for patients with diabetes within the hospital eye 
service, which may be directly useful to clinical practice and 
service provision. Further analysis may enable early identifica-
tion of high-risk groups, stratification of frequency of follow-up 
and more targeted intervention to avoid the development of 
blindness in those at highest risk.
While our use of the IMD tool and the ‘real world’ EMR-based 
design has considerable advantages, we recognise that they are 
not without their challenges and limitations. The IMD tool is 
based on geographical area, which means that deprivation is 
defined by ‘neighbourhood’ and not by household or by the 
individual. Under some circumstances individuals may live in 
a neighbourhood that is somewhat different from their own 
deprivation status. This risk is however reduced by the small 
size of the areas used (LSOA). Since 2000 the UK government 
has found the IMD tool to be a reliable and valuable measure 
of deprivation within England, with good internal and external 
validity justifying its ongoing usage.37
The main challenge arising from most ‘real world’ studies such 
as ours is the quality assurance of data. While we recognise that 
quality assurance may not be of the same level as a randomised 
controlled trial, there are a number of characteristics of our 
study that provide reassurance in this regard. First, the EMR 
design ensures that the data entry is structured, with key fields 
being compulsory and low rates of missing non-compulsory 
fields.32 Second, data fields have value cut-offs to stop major 
data entry errors; most minor errors may occur in either direc-
tion and any effect is minimised by the large size of the study. 
Overall we would argue that we achieve a high ‘signal:noise’ 
ratio in this real-world study through the design of the under-
lying data capture tool (through the EMR system) and the scale 
of the study incorporating a large number of patients over many 
different centres across the UK.28–30
In summary, this analysis of a real-world data set from a large 
number of centres across the UK indicates an association that 
those people with diabetes and higher levels of deprivation are 
more likely to present to the hospital eye service with worse 
visual acuity and binocular visual status. The presence of this 
‘deprivation effect’ on the level of vision at the first point of 
contact with a specialist eye service is a concern. We also iden-
tified an apparent interaction between pattern of treatment 
for sight-threatening complications of diabetes and level of 
deprivation.
It is important to note that our analysis was conducted within 
a universal ‘free’ system (the UK NHS) and that this effect may 
be more pronounced in countries where there is differential 
access to healthcare based on ability to pay. The recognition of 
a ‘deprivation effect’ on diabetic eye disease within different 
societies may help policy makers direct appropriate interven-
tions and resources to the most vulnerable, and help reduce the 
inequality of outcome.
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